Optimal Diagnostic Measures and Thresholds for Hypogonadism in Men With HIV/AIDS: Comparison Between 2 Transdermal Testosterone Replacement Therapy Gels

References

• . Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–769
   PubMed Web of Science ®Google Scholar
• . AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8(6):439–456
   Google Scholar
• . Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89(8):3813–3817
   PubMedGoogle Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559
   PubMed Web of Science ®Google Scholar
• . Baum NH, Crespi CA. Testosterone replacement in elderly men. Geriatrics. 2007;62(9):15–18
   PubMedGoogle Scholar
• . Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab. 1998;12(3):379–390
   PubMedGoogle Scholar
• . Grinspoon S. Androgen deficiency and HIV infection. Clin Infect Dis. 2005;41(12):1804–1805
   PubMedGoogle Scholar
• . Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3(5):377–384
   PubMed Web of Science ®Google Scholar
• . Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male. 2008;11(3):107–117
   PubMed Web of Science ®Google Scholar
• . Dandona P, Dhindsa S, Chandel A, Chaudhuri A. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med. 2009;121(3):45–51
   PubMed Web of Science ®Google Scholar
• . Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41(12):1794–1803
   PubMedGoogle Scholar
• . Bhasin S, Cunningham GR, Hayes FJ, . Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010
   PubMed Web of Science ®Google Scholar
• . Braunstein GD. Testes. In: Greenspan FS, Strewler GJ, eds. Basic and Clinical Endocrinology. 5th ed. Stamford, CT: Appleton and Lange, 1997:403–433
   Google Scholar
• . Feldman HA, Longcope C, Derby CA, . Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–598
   PubMed Web of Science ®Google Scholar
• . Yeap BB, Almeida OP, Hyde Z, . In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007;156(5):585–594
   PubMed Web of Science ®Google Scholar
• . Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73(5):1016–1025
   PubMed Web of Science ®Google Scholar
• . Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–731
   PubMed Web of Science ®Google Scholar
• . Dobs AS, Few WL 3rd, Blackman MR, Harman SM, Hoover DR Graham NM. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab. 1996;81(11):4108–4112
   PubMed Web of Science ®Google Scholar
• . Wang C, Cunningham G, Dobs A, . Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–2098
   PubMed Web of Science ®Google Scholar
• . Ensrud KE, Lewis CE, Lambert LC, . Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int. 2006;17(9):1329–1336
   PubMedGoogle Scholar
• . LeBlanc ES, Nielson CM, Marshall LM, . The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337–3346
   PubMed Web of Science ®Google Scholar
• . Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378–387
   PubMed Web of Science ®Google Scholar
• . Meier C, Nguyen TV, Handelsman DJ, . Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168(1):47–54
   PubMedGoogle Scholar
• . Darby E, Anawalt BD. Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293–309
   PubMedGoogle Scholar
• . Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007;13(6):629–635
   PubMedGoogle Scholar
• . Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906
   PubMed Web of Science ®Google Scholar
• . English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911
   PubMed Web of Science ®Google Scholar
• . Clay PG, Voss LE, Williams C, Daume EC. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother. 2008;42(5):670–679
   PubMedGoogle Scholar
• . Grinspoon S, Corcoran C, Lee K, . Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81(11):4051–4058
   PubMed Web of Science ®Google Scholar
• . Grinspoon S, Corcoran C, Askari H, . Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129(1):18–26
   PubMed Web of Science ®Google Scholar
• . Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2(11):692–699
   PubMedGoogle Scholar
• . Tebas P, Powderly WG, Claxton S, . Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14(4):F63–F67
   PubMed Web of Science ®Google Scholar
• . Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174
   PubMed Web of Science ®Google Scholar
• . Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14(2):165–179
   PubMed Web of Science ®Google Scholar
• . Grijsen ML, Vrouenraets SM, Steingrover R, . High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010;24(14):2233–2238
   PubMed Web of Science ®Google Scholar
• . Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617–623
   PubMed Web of Science ®Google Scholar
• . McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24(9):1367–1370
   PubMed Web of Science ®Google Scholar
• . Simioni S, Cavassini M, Annoni JM, . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250
   PubMed Web of Science ®Google Scholar
• . Antinori A, Arendt G, Becker JT, . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799
   PubMed Web of Science ®Google Scholar
• . Robertson KR, Smurzynski M, Parsons TD, . The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915–1921
   PubMed Web of Science ®Google Scholar
• . McNicholas T, Ong T. Review of Testim gel. Expert Opin Pharmacother. 2006;7(4):477–484
   PubMed Web of Science ®Google Scholar
• . Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20(2):213–217
   PubMedGoogle Scholar
• . Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther. 2005;27(3):286–298
   PubMedGoogle Scholar
• . Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol. 1974;3(1):69–96
   PubMed Web of Science ®Google Scholar
• . Laaksonen DE, Niskanen L, Punnonen K, . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–1041
   PubMed Web of Science ®Google Scholar
• . Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90(5):2618–2623
   PubMed Web of Science ®Google Scholar
• . Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91(3):843–850
   PubMed Web of Science ®Google Scholar
• . Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827–834
   PubMed Web of Science ®Google Scholar
• . Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6(1): 1–7
   PubMedGoogle Scholar
• . Laaksonen DE, Niskanen L, Punnonen K, . The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712–719
   PubMed Web of Science ®Google Scholar
• . Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004;6(3):208–215
   PubMed Web of Science ®Google Scholar
• . Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318
   PubMed Web of Science ®Google Scholar
• . Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005;5(3):141–154
   PubMedGoogle Scholar
• . Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079
   PubMed Web of Science ®Google Scholar
• . Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos. 2003;24(3):115–120
   PubMed Web of Science ®Google Scholar
• . Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003;6(3):207–211
   PubMedGoogle Scholar
• . El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005;2(2):235–240
   PubMed Web of Science ®Google Scholar
• . Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006;18(2):201–205
   PubMedGoogle Scholar
• . Ross AC, Armentrout R, O'Riordan MA, . Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr. 2008;49(5):499–506
   PubMedGoogle Scholar
• . Lo J, Abbara S, Shturman L, . Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243–253
   PubMed Web of Science ®Google Scholar
• . Stein JH, Klein MA, Bellehumeur JL, . Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104(3):257–262
   PubMed Web of Science ®Google Scholar
• . Fukui M, Kitagawa Y, Nakamura N, . Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26(6):1869–1873
   PubMedGoogle Scholar
• . Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201
   PubMed Web of Science ®Google Scholar
• . Kang SM, Jang Y, Kim JY, . Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol. 2002;89(7):862–864
   PubMed Web of Science ®Google Scholar
• . Gladh YM, Rahgozar M, Hammar ML, Fredriksson MG, Spetz AC. Prevalence of symptoms possibly related to PADAM, in a Swedish population aged 55, 65 and 75 years. Maturitas. 2005;50(3):161–166
   PubMedGoogle Scholar
• . Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75
   PubMed Web of Science ®Google Scholar